Event-free survival curves for HHF and renal events.

Kaplan-Meier curves comparing the risk of (A) HHF, (B) composite renal events, and (C) composite HHF and renal events between the 3 groups. CI, confidence interval; HHF, hospitalization for heart failure; HR, hazard ratio; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p

Clinical outcomes.

Clinical outcomes.</p

Study data.

(XLSX)</p

Study flowchart.

After 1:1:2 propensity score matching, there were 921 patients treated with empagliflozin, 921 patients treated with dapagliflozin, and 1,842 patients treated with DPP4i (control group). ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; DPP4i, dipeptidyl peptidase-4 inhibitor; HF, heart failure; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p

Changes in laboratory findings.

Serial changes in (A) total cholesterol, (B) LDL cholesterol, (C) HbA1c, and (D) GFR are plotted according to group. GFR, glomerular filtration rate; HbA1c, glycosylated hemoglobin; LDL, low-density lipoprotein; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p

Event-free survival curves for atherosclerotic events.

Kaplan-Meier curves comparing the risk of (A) composite coronary events and (B) composite ischemic events between the 3 groups. CI, confidence interval; HR, hazard ratio; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p

Multivariable predictors of ischemic events.

Multivariable predictors of ischemic events.</p

Multivariable predictors of HF and renal events.

Multivariable predictors of HF and renal events.</p

Baseline characteristics.

Baseline characteristics.</p